Managing type 2 diabetes has entered a new era with innovative treatments that combine effectiveness with convenience. Rybelsus, developed by Novo Nordisk, marks a significant breakthrough in diabetes care as the first oral GLP-1 agonist in tablet form. This next-generation formulation has expanded treatment options for patients across the UK who previously relied solely on injectable...